It's crunch time for biotech projects started on a bet that the industry would shake off its multiyear malaise.

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

News of the layoffs come just one day after the company reported a 5% year over year revenue increase — boosting revenue to ...

Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Years of a back-and-forth battle over Mexico’s plan to ban imports of corn grown with biotech and glyphosate is finally, ...

Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...